Related Experiment Video
Updated: Jan 10, 2026
13:22
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
8.2K
Inflammation-activated protein kinases as targets for drug development
1Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, University of California, San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093-0723, USA. karinoffice@ucsd.edu
Proceedings of the American Thoracic Society
|November 4, 2005
Summary
Novel anti-inflammatory drugs targeting IkappaB kinase and mitogen-activated protein kinases show promise for treating chronic inflammatory diseases. Further research is needed to understand mechanisms and potential complications.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Chronic inflammatory diseases are prevalent and debilitating, necessitating new therapeutic targets.
- Nuclear factor-kappaB (NF-κB) signaling is a key pathway controlling inflammation-associated gene expression.
- Interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α) are critical pro-inflammatory cytokines.
Purpose of the Study:
- To review novel therapeutic targets for anti-inflammatory drug development.
- To explore the role of IkappaB kinase (IKK) and mitogen-activated protein kinases (MAPKs) in inflammation.
- To discuss potential mechanisms and complications of targeting these pathways.
Main Methods:
- Review of existing literature on inflammatory signaling pathways.
- Analysis of preclinical data on inhibitors targeting IKK and MAPKs.
- Focus on cell type-specific inactivation of IKK beta-catalytic subunit.
Main Results:
- Inhibition of IKK demonstrates potent anti-inflammatory activity, consistent with preclinical findings.
- MAPK pathways are also implicated in the expression of key pro-inflammatory cytokines.
- Preliminary data suggest that inhibitors targeting these pathways exhibit anti-inflammatory effects.
Conclusions:
- Targeting IKK and MAPK pathways represents a promising strategy for novel anti-inflammatory therapeutics.
- Understanding the precise mechanisms of action is crucial for drug development.
- Potential complications associated with these inhibitors require careful consideration.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
01:20The JAK-STAT Signaling Pathway
11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.8K
01:07MAPK Signaling Cascades
7.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
01:25cAMP-dependent Protein Kinase Pathways
8.2K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.2K
01:19Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K